RYTM
Rhythm Pharmaceuticals Inc
2 of the 83 super-investors we track hold RYTM, worth a combined $163M per their latest 13F filings. The largest position: Stanley Druckenmiller at 0.5% of their portfolio. This quarter the cohort logged 1 buy and 0 sells on the name. Conviction score: 47 of 100 (how strongly the cohort backs it) — ranked #54 of 742 stocks. Conviction rising: 1 more super-investor hold it than in 2026Q1.
Why super-investors own RYTM
RYTM is held by 2 super-investors in our cohort, with a combined position value of $163M. The highest-conviction owner is Stanley Druckenmiller at 0.5% of their portfolio. Cohort ownership has grown from 1 to 2 over the last four quarters — net interest is rising. This quarter the cohort registered 1 new positions.
AI-synthesized from 13F filings. Not investment advice.
Cohort owners over time
2017Q4 → 2026Q2How many of the cohort members held this stock each quarter.
Owners (2) · click any column to sort
| #↑ | Manager | % Port. | History | Value | Shares |
|---|---|---|---|---|---|
| 1 | Joel Greenblatt | 0.1% | 26q | $140M | 1,263,652 |
| 2 | Stanley Druckenmiller | 0.5% | — 1q | $23M | 203,618 |
Owners of RYTM also hold
Recent activity (1)
| Manager | Move | % Port. | Δ Shares | Value | Filed |
|---|---|---|---|---|---|
| Stanley Druckenmiller | NEW | 0.5% | +100% | $23M | Aug 14, 2026 |
Long US equity 13F-HR filings only. CUSIP 76243J105. Not investment advice.